RegulatoryDEA files post-hearing brief recommending marijuana be moved to Schedule IIIRegulatoryGermany's medical cannabis insurance reform descends into regulatory disputeStudyPhase 3 trial of full-spectrum cannabis extract VER-01 for chronic low back pain published in Nature MedicineStudyUniversity of Sydney trial: cannabidiol significantly reduces chronic pain in people with nerve damageRegulatoryTGA responds to medicinal cannabis review, signalling overhaul of Australian access pathwaysBusinessFDA grants Breakthrough Therapy Designation to plant-derived cannabis extract for pain treatmentBusinessTilray expands cultivation capacity and updates guidance on German medical cannabis marketBusinessDunbar Pharma launches first plant-derived dronabinol in UK through IPS PharmaStudyAnanda Pharma's ENDOCAN study explores pharmaceutical-grade CBD for endometriosis careRegulatoryCongressional researchers note FDA has missed deadline to publish hemp cannabinoid lists and container guidanceRegulatoryDEA files post-hearing brief recommending marijuana be moved to Schedule IIIRegulatoryGermany's medical cannabis insurance reform descends into regulatory disputeStudyPhase 3 trial of full-spectrum cannabis extract VER-01 for chronic low back pain published in Nature MedicineStudyUniversity of Sydney trial: cannabidiol significantly reduces chronic pain in people with nerve damageRegulatoryTGA responds to medicinal cannabis review, signalling overhaul of Australian access pathwaysBusinessFDA grants Breakthrough Therapy Designation to plant-derived cannabis extract for pain treatmentBusinessTilray expands cultivation capacity and updates guidance on German medical cannabis marketBusinessDunbar Pharma launches first plant-derived dronabinol in UK through IPS PharmaStudyAnanda Pharma's ENDOCAN study explores pharmaceutical-grade CBD for endometriosis careRegulatoryCongressional researchers note FDA has missed deadline to publish hemp cannabinoid lists and container guidance
About

International education for cannabinoid medicine.

The Institute for Cannabinoid Therapy is an educational organisation dedicated to advancing the safe and responsible practice of cannabinoid therapeutics through rigorous professional education.

Mission

To advance the international education of healthcare professionals in the science and clinical practice of cannabinoid medicine.

Vision

A global community of practitioners equipped to make evidence-based, responsible and safe decisions in cannabinoid therapeutics.

Educational philosophy

Rigorous, evidence-based curriculum authored by practising clinicians and scientists, delivered under academic direction.

Scientific integrity

Educator selection, curriculum development and regulatory reviews are grounded in transparent, peer-reviewed practice.

International collaboration

Educators from multiple jurisdictions ensure a genuinely comparative and global perspective.

Academic leadership

Curriculum direction, module content and teaching are set by our academic leadership. Where industry sponsorship supports specific case-study material, learning objectives remain in academic hands.